SCHEMBL6401879

SCHEMBL6401879

O=C(CCCc1cccc(O)c1)c1c(O)cc(O)cc1OP(=O)(O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CBS P35520 1/20 0.50
ACHE P22303 4/20 0.45
SGMS1 Q86VZ5 4/20 0.45
SGMS2 Q8NHU3 4/20 0.45
SLC5A1 P13866 6/20 0.45
SLC5A2 P31639 5/20 0.45
GAA P10253 2/20 0.45
MAPT P10636 2/20 0.45
CYP19A1 P11511 3/20 0.42
HDAC6 Q9UBN7 1/20 0.41
TYR P14679 2/20 0.41
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
SLC16A3 O15427 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
TTR P02766 1/20 0.40
ESR1 P03372 1/20 0.40
TP53 P04637 1/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6394384 0.93 SLC5A1 (0.53) CBSSLC5A1SLC5A2GAAMAPT
SCHEMBL6395137 0.89 ACHE (0.47) CBSACHESGMS1SGMS2SLC5A1
SCHEMBL6397107 0.87 ACHE (0.61) CBSACHESGMS1SGMS2SLC5A1
SCHEMBL6395053 0.85 MAPT (0.47) CBSSLC5A1SLC5A2GAAMAPT
SCHEMBL6403588 0.83 MEN1 (0.45) HDAC6MEN1KMT2AAKR1B10AKR1B1
SCHEMBL6397103 0.82 CBS (0.53) CBSACHESGMS1SGMS2SLC5A1
SCHEMBL6403786 0.82 SLC5A1 (0.45) ACHESGMS1SGMS2SLC5A1SLC5A2
SCHEMBL6401472 0.82 MGLL (0.44) CBSGAAHDAC6TYRPOLB
SCHEMBL6398398 0.82 SLC28A3 (0.44) HDAC6TYRPOLBSLC28A3AKR1B10
SCHEMBL6402197 0.81 HDAC6 (0.43) HDAC6KDM4EMEN1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed
EP-1175425-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-01-30 EP disclosed
WO-2000043402-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 CBS 2924/4885ACHE 4868/4885SGMS1 3968/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 CBS 2750/4885ACHE 4865/4885SGMS1 4101/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 CBS 2924/4885ACHE 4868/4885SGMS1 3968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.